|
Status |
Public on Dec 31, 2019 |
Title |
input DNA_1 |
Sample type |
SRA |
|
|
Source name |
Androgen dependent prostate cancer cell line
|
Organism |
Homo sapiens |
Characteristics |
cell line: LNCaP-FGC cell type: Androgen dependent prostate cancer cell line treatment: DMSO chip antibody: None
|
Treatment protocol |
LNCaP cells were divided into 4 different drug treatment groups (including control) and were treated with I-CBP112 and/or A-485 for 24 h.
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Chromatin shearing followed by p300 immunoprecipitation. Swift Biosciences Accel-NGS 2S
|
|
|
Library strategy |
ChIP-Seq |
Library source |
genomic |
Library selection |
ChIP |
Instrument model |
Illumina NextSeq 500 |
|
|
Data processing |
ChiLin pipeline. QC with FastQC. Align with Bowtie. Peak calling by MACS2. Pearson correlation with wigCorrelate; %overlap between replicates determined. Peaks annotated with HOMER after removal of blacklisted regions. Genome_build: hg19 (GRCh37) Supplementary_files_format_and_content: bigWig
|
|
|
Submission date |
Jan 03, 2019 |
Last update date |
Dec 31, 2019 |
Contact name |
Beth Zucconi |
E-mail(s) |
bethzucconi@gmail.com
|
Organization name |
Brigham & Women's Hospital
|
Department |
Medicine
|
Lab |
P.A. Cole
|
Street address |
77 Avenue Louis Pasteur, NRB 164
|
City |
Boston |
State/province |
Massachusetts |
ZIP/Postal code |
02115 |
Country |
USA |
|
|
Platform ID |
GPL18573 |
Series (2) |
GSE124642 |
Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP [ChIP-seq] |
GSE124644 |
Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP |
|
Relations |
BioSample |
SAMN10690552 |
SRA |
SRX5199668 |